The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin

NCT00031343 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

128

Enrollment

NIH

Sponsor class

Conditions

HIV Infections
Hepatitis C

Interventions

DRUG: highly active antiretroviral therapy (HAART)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)